Towards a long-lasting immune prevention of HER2 mammary carcinomas: directions from transgenic mice - PubMed (original) (raw)
Affiliations
- PMID: 15153804
Review
Towards a long-lasting immune prevention of HER2 mammary carcinomas: directions from transgenic mice
Raffaele A Calogero et al. Cell Cycle. 2004 Jun.
Abstract
Several theoretical and practical issues differentiate immune prevention from tumor immune therapy. The latter seeks to induce a rapid reaction against a life-threatening tumor, whereas prevention is dictated by the need to maintain constant surveillance of a situation in which an event is foreseen, but may not occur. The time frame of successful prevention is therefore long and often lifelong. Time itself is thus a key factor in the elaboration of vaccines to prevent tumor growth and its great length in preventive management poses new immunological problems that cannot be studied in short-term vaccination-challenge experiments. Many recent data indicate that HER2 receptor displays several features of an ideal tumor associated antigen and that an immune response can significantly alter HER2 tumor progression. We are thus using vaccination in the immune prevention and cure of carcinomas in HER2 transgenic mice in the search for a rationale for the application of preventive and curative vaccination for patients with HER2/ErbB-2 neoplastic lesions or at risk of recurrence after successful surgery. The design of effective immunopreventive approaches that can be translated to human situations is an important issue. A molecularly defined, effective and validated anti HER2 vaccine and the definition of immune mechanisms leading to the inhibition of HER2-driven neoplastic proliferation may provide a new way of treating these patients.
Similar articles
- Prime-boost vaccination with plasmid and adenovirus gene vaccines control HER2/neu+ metastatic breast cancer in mice.
Wang X, Wang JP, Rao XM, Price JE, Zhou HS, Lachman LB. Wang X, et al. Breast Cancer Res. 2005;7(5):R580-8. doi: 10.1186/bcr1199. Epub 2005 May 23. Breast Cancer Res. 2005. PMID: 16168101 Free PMC article. - Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2.
De Giovanni C, Nicoletti G, Quaglino E, Landuzzi L, Palladini A, Ianzano ML, Dall'Ora M, Grosso V, Ranieri D, Laranga R, Croci S, Amici A, Penichet ML, Iezzi M, Cavallo F, Nanni P, Lollini PL. De Giovanni C, et al. Breast Cancer Res. 2014 Jan 23;16(1):R10. doi: 10.1186/bcr3602. Breast Cancer Res. 2014. PMID: 24451168 Free PMC article. - An HER2 DNA vaccine with evolution-selected amino acid substitutions reveals a fundamental principle for cancer vaccine formulation in HER2 transgenic mice.
Jones RF, Reyes JD, Gibson HM, Jacob JB, Vaishampayan U, Ratner S, Chen K, Wei WZ. Jones RF, et al. Cancer Immunol Immunother. 2019 Jul;68(7):1143-1155. doi: 10.1007/s00262-019-02333-9. Epub 2019 Jun 8. Cancer Immunol Immunother. 2019. PMID: 31177328 Free PMC article. - Expansion of HER2/neu-specific T cells ex vivo following immunization with a HER2/neu peptide-based vaccine.
Knutson KL, Disis ML. Knutson KL, et al. Clin Breast Cancer. 2001 Apr;2(1):73-9. doi: 10.3816/CBC.2001.n.014. Clin Breast Cancer. 2001. PMID: 11899386 Review. - [Anti-HER2 vaccines: The HER2 immunotargeting future?].
Ladjemi MZ, Jacot W, Pèlegrin A, Navarro-Teulon I. Ladjemi MZ, et al. Pathol Biol (Paris). 2011 Jun;59(3):173-82. doi: 10.1016/j.patbio.2009.04.002. Epub 2009 May 28. Pathol Biol (Paris). 2011. PMID: 19481373 Review. French.
Cited by
- Comparison of prophylactic and therapeutic immunisation with an ErbB-2 (HER2) fusion protein and immunoglobulin V-gene repertoire analysis in a transgenic mouse model of spontaneous breast cancer.
Mukhopadhyay A, Dyring C, Stott DI. Mukhopadhyay A, et al. Vaccine. 2014 Feb 12;32(8):1012-8. doi: 10.1016/j.vaccine.2013.10.077. Epub 2013 Nov 11. Vaccine. 2014. PMID: 24231440 Free PMC article. - Unlocking the power of cross-species genomic analyses: identification of evolutionarily conserved breast cancer networks and validation of preclinical models.
Bennett CN, Green JE. Bennett CN, et al. Breast Cancer Res. 2008;10(5):213. doi: 10.1186/bcr2125. Epub 2008 Sep 11. Breast Cancer Res. 2008. PMID: 18828875 Free PMC article. Review. - Prime-boost vaccination with plasmid and adenovirus gene vaccines control HER2/neu+ metastatic breast cancer in mice.
Wang X, Wang JP, Rao XM, Price JE, Zhou HS, Lachman LB. Wang X, et al. Breast Cancer Res. 2005;7(5):R580-8. doi: 10.1186/bcr1199. Epub 2005 May 23. Breast Cancer Res. 2005. PMID: 16168101 Free PMC article. - Immune prevention of mammary carcinogenesis in HER-2/neu transgenic mice: a microarray scenario.
Astolfi A, Rolla S, Nanni P, Quaglino E, De Giovanni C, Iezzi M, Musiani P, Forni G, Lollini PL, Cavallo F, Calogero RA. Astolfi A, et al. Cancer Immunol Immunother. 2005 Jun;54(6):599-610. doi: 10.1007/s00262-004-0635-4. Epub 2005 Feb 3. Cancer Immunol Immunother. 2005. PMID: 15690207 Free PMC article. - Harnessing host immune responses to preneoplasia: promise and challenges.
Dhodapkar MV. Dhodapkar MV. Cancer Immunol Immunother. 2005 May;54(5):409-13. doi: 10.1007/s00262-004-0607-8. Epub 2004 Dec 16. Cancer Immunol Immunother. 2005. PMID: 15602654 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Research Materials
Miscellaneous